FDA declines to grant accelerated approval for Eli Lilly's experimental Alzheimer's treatment | CNN

The US Food and Drug Administration declined to grant accelerated approval to an experimental Alzheimer’s drug, donanemab, and requested additional data from Eli Lilly and Company, the drug maker. The company, which announced the development on Thursday, plans to file Phase 3 clinical trial data later this year for a traditional FDA approval.

The Alzheimer’s Drug Discovery Foundation released a statement Thursday in response to the FDA decision, describing it as being due to “the limited number of patients” who stayed on donanemab for at least 12 months, which is the timeframe the FDA wants to see to assess the drug’s safety.

I hope Nuremberg2 comes soon enough for the graphene shot depopulation agenda pushers.

Joe is a Joke!

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA declines to give accelerated approval to Eli Lilly’s Alzheimer’s drug, firm saysThe Food and Drug Administration said it needed safety data on more patients, the company said. Wish US_FDA had looked for more data on the COVID vaccines from Moderna and Pfizer.
Source: washingtonpost - 🏆 95. / 72 Read more »

Why the FDA rejected Eli Lilly's attempt for quick approval of Alzheimer's drugWith more than 6 million Americans afflicted with the mind-robbing disease, families and caregivers have been desperate for a drug proven to slow the disease after years of clinical trial failures.
Source: USATODAY - 🏆 100. / 63 Read more »

Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analystsThe U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said.
Source: Reuters - 🏆 2. / 97 Read more »